Tobin W. Juvenal Sells 3,507 Shares of Castle Biosciences, Inc. (NASDAQ:CSTL) Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin W. Juvenal sold 3,507 shares of the company’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $35.56, for a total transaction of $124,708.92. Following the completion of the transaction, the insider now owns 54,178 shares in the company, valued at approximately $1,926,569.68. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Castle Biosciences Price Performance

CSTL traded up $0.65 on Thursday, hitting $33.31. 385,114 shares of the stock were exchanged, compared to its average volume of 324,657. Castle Biosciences, Inc. has a 12 month low of $16.20 and a 12 month high of $35.84. The business has a 50-day moving average of $30.78 and a two-hundred day moving average of $25.72. The company has a debt-to-equity ratio of 0.02, a current ratio of 8.12 and a quick ratio of 7.92. The firm has a market capitalization of $919.69 million, a price-to-earnings ratio of 168.06 and a beta of 0.99.

Castle Biosciences (NASDAQ:CSTL) last posted its earnings results on Monday, November 4th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.14. The firm had revenue of $85.78 million during the quarter, compared to analysts’ expectations of $78.55 million. Castle Biosciences had a net margin of 1.95% and a return on equity of 1.50%. During the same quarter in the prior year, the business earned ($0.26) earnings per share. Sell-side analysts forecast that Castle Biosciences, Inc. will post -0.58 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

CSTL has been the topic of several research reports. KeyCorp upped their price objective on shares of Castle Biosciences from $28.00 to $36.00 and gave the company an “overweight” rating in a report on Tuesday. BTIG Research upped their price objective on shares of Castle Biosciences from $35.00 to $40.00 and gave the company a “buy” rating in a report on Monday, October 14th. Lake Street Capital upped their price objective on shares of Castle Biosciences from $34.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday. Robert W. Baird upped their price target on shares of Castle Biosciences from $37.00 to $39.00 and gave the company an “outperform” rating in a research note on Tuesday. Finally, Scotiabank upped their price target on shares of Castle Biosciences from $37.00 to $44.00 and gave the company a “sector outperform” rating in a research note on Wednesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Castle Biosciences currently has an average rating of “Buy” and a consensus target price of $37.88.

Institutional Trading of Castle Biosciences

Several hedge funds have recently modified their holdings of the stock. Principal Financial Group Inc. increased its stake in shares of Castle Biosciences by 2.7% in the 3rd quarter. Principal Financial Group Inc. now owns 1,538,520 shares of the company’s stock valued at $43,879,000 after acquiring an additional 40,377 shares in the last quarter. Vanguard Group Inc. increased its stake in Castle Biosciences by 2.2% during the 1st quarter. Vanguard Group Inc. now owns 1,494,176 shares of the company’s stock valued at $33,096,000 after purchasing an additional 32,695 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Castle Biosciences by 8.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 809,934 shares of the company’s stock valued at $17,631,000 after purchasing an additional 60,675 shares in the last quarter. Renaissance Technologies LLC increased its stake in Castle Biosciences by 47.3% during the 2nd quarter. Renaissance Technologies LLC now owns 301,500 shares of the company’s stock valued at $6,564,000 after purchasing an additional 96,800 shares in the last quarter. Finally, Acadian Asset Management LLC increased its stake in Castle Biosciences by 33.0% during the 2nd quarter. Acadian Asset Management LLC now owns 280,497 shares of the company’s stock valued at $6,101,000 after purchasing an additional 69,673 shares in the last quarter. Institutional investors own 92.60% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc, a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus.